确定类风湿关节炎当代药物审批试验中最合适的ACR应答定义
该研究系统检索EMBASE、Medline和Cochrane图书馆的随机对照类风湿关节炎药物审批试验,纳入45项分析,用混合效应逻辑回归比较ACR20、ACR50和ACR70在不同时间点的判别效度。结果显示ACR20在各时间点判别能力均高,ACR50和ACR70在安慰剂对照期末判别力最高;作者认为若关注早期判别ACR20仍最强,若评估较晚时间点则支持选择更严格阈值。
要点
- ACR20在所有时间点判别能力均高,是活动治疗与安慰剂间最强判别指标。
- ACR50和ACR70在安慰剂对照期末判别力最高,且临床表面效度更高。
- 与DMARD经治应答不足人群相比,DMARD初治人群对治疗应答更快。
核心结论
- ACR20仍是区分活动治疗与安慰剂最有力的指标,尤其当早期判别为主要关注点时。
- 若评估较晚时间点,作者支持选择更严格阈值,因其判别力相当但临床表面效度更高。
研究设计与样本
- 系统检索EMBASE、Medline和Cochrane图书馆的生物制剂和靶向合成DMARD类随机对照类风湿关节炎药物审批试验。
- 纳入报告24周安慰剂对照期内多个时间点ACR应答率的全文文章,共筛查12680条记录,最终纳入45项分析。
- 使用混合效应逻辑回归计算各结局和各时间点的ACR应答者比例,并比较这些指标在多个时间点的判别效度。
主要发现
- ACR20在所有时间点的判别能力均高。
- ACR50和ACR70在安慰剂对照期末判别力最高。
- 该效应在所有患者人群和化合物组中均可观察到。
- 与DMARD经治应答不足人群相比,DMARD初治人群对治疗应答更快。
关键数值与推荐
- ACR20在所有时间点判别能力高。
- ACR50和ACR70在安慰剂对照期末判别力最高。
临床怎么用
- 作者结论认为,ACR20仍是活动治疗与安慰剂间最有力的判别指标,尤其当早期判别为主要关注点时。
- 作者结论支持在评估较晚时间点时选择更严格阈值,因其判别力相当但临床表面效度更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate which American College of Rheumatology (ACR) response definition (ACR20, 50 or 70) should primarily be used for efficacy claims in future drug approval trials of rheumatoid arthritis (RA). METHODS: We systematically searched EMBASE, Medline and the Cochrane Library for randomised controlled RA drug approval trials of biological and targeted synthetic disease-modifying antirheumatic drugs (DMARDs). We included full-text articles reporting ACR response rates for multiple time points over a 24-week placebo-controlled period and visualised normalised response trajectories over time in different patient populations. Using mixed-effect logistic regression, we calculated the proportion of ACR responders per outcome and time point, and compared the discriminant validity of these metrics at multiple time points. RESULTS: We screened 12 680 records and included 45 in the final analysis. Discriminative capacity of the ACR20 was high across all time points, whereas ACR50 and ACR70 showed highest discrimination towards the end of the placebo-controlled periods. This effect could be observed in all patient populations and compound groups. Faster response to treatment was observed in DMARD naïve patient populations when compared with DMARD insufficient responders. CONCLUSION: ACR20 remains the most powerful discriminator between active treatment and placebo, especially when early discrimination is of primary interest. At the same time, our results support the selection of more stringent thresholds if later time points shall be evaluated, given their comparable discriminant but higher clinical face validity.
引用
- Konzett V, Kerschbaumer A, Smolen JS, et al. Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis. Ann Rheum Dis. 2024. PMID: 37758287. doi:10.1136/ard-2023-224477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。